Immunomodulatory functions of mesenchymal stem cells and possible mechanisms

Histology and Histopathology

Volumn 31, Issue 9, 2016, Pages 949-959

  Wang, Qing ^a,b   Ding, Gang ^c   Xu, Xin ^a  

^a People's Republic of China   (China)

^b WEIFANG PEOPLE'S HOSPITAL   (China)

^c WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

Cell therapy; Immunomodulation; Mesenchymal stem cells; Regenerative medicine

Indexed keywords

ANIMAL; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; MESENCHYMAL STROMA CELL;

ANIMALS; HUMANS; IMMUNOMODULATION; MESENCHYMAL STROMAL CELLS;

EID: 84977478981     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: 10.14670/HH-11-750     Document Type: Review

References (112)

1. Aggarwal S. and Pittenger M.F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822
2. Aldinucci A., Rizzetto L., Pieri L., Nosi D., Romagnoli P., Biagioli T., Mazzanti B., Saccardi R., Beltrame L., Massacesi L., Cavalieri D. and Ballerini C. (2010). Inhibition of immune synapse by altered dendritic cell actin distribution: a new pathway of mesenchymal stem cell immune regulation. J. Immunol. 185, 5102-5110
3. Angoulvant D., Clerc A., Benchalal S., Galambrun C., Farre A., Bertrand Y. and Eljaafari A. (2004). Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 41, 469-476
4. Anjos-Afonso F. and Bonnet D. (2007). Nonhematopoietic/endothelial SSEA-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood 109, 1298-1306
5. Asari S., Itakura S., Ferreri K., Liu C.P., Kuroda Y., Kandeel F. and Mullen Y. (2009). Mesenchymal stem cells suppress B-cell terminal differentiation. Exp. Hematol. 37, 604-615
6. Awasthi A. and Kuchroo V.K. (2009). Th17 cells: from precursors to players in inflammation and infection. Int. Immunol. 21, 489-498
7. Bai L., Lennon D.P., Eaton V., Maier K., Caplan A.I., Miller S.D. and Miller R.H. (2009). Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 57, 1192-1203
8. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., Deans R., Moseley A. and Hoffman R. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30, 42-48
9. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., Galun E. and Rachmilewitz J. (2005). Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105, 2214-2219
10. Bieback K., Kem S., Kluter H. and Eichler H. (2004). Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells 22, 625-634
11. Brandau S., Jakob M., Hemeda H., Bruderek K., Janeschik S., Bootz F. and Lang S. (2010). Tissue-resident mesenchymal stem cells attract peripheral blood neutrophils and enhance their inflammatory activity in response to microbial challenge. J. Leukoc. Biol. 88, 1005-1015
12. Budoni M., Fierabracci A., Luciano R., Petrini S., Di Ciommo V. and Muraca M. (2013). The immunosuppressive effect of mesenchymal stromal cells on B lymphocytes is mediated by membrane vesicles. Cell Transplant. 22, 369-379
13. Caplan A.I. (1991). Mesenchymal stem cells. J. Orthop. Res. 9, 641-650
14. Caplan A.I. and Bruder S.P. (2001). Mesenchymal stem cells: building blocks for moleculars medicine in the 21st century. Trends Mol. Med. 7, 259-264
15. Cassatella M.A., Mosna F., Micheletti A., Lisi V., Tamassia N., Cont C., Calzetti F., Pelletier M., Pizzolo G. and Krampera M. (2011). Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells 29, 1001-1011
16. Chabannes D., Hill M., Merieau E., Rossignol J., Brion R., Soulillou J.P., Anegon I. and Cuturi M.C. (2007). A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 110, 3691-3694
17. Chan J.L., Tang K.C., Patel A.P., Bonilla L.M., Pierobon N., Ponzio N.M. and Rameshwar P. (2006). Antigen-presenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 107, 4817-4824
18. Chen C.P., Chen Y.Y., Huang J.P. and Wu Y.H. (2014). The effect of conditioned medium derived from human placental multipotent mesenchymal stromal cells on neutrophils: possible implications for placental infection. Mol. Hum. Reprod. 20, 1117-1125
19. Chen L., Tredget E.E., Wu P.Y. and Wu Y. (2008). Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 3, e1886
20. Comoli P., Ginevri F., Maccario R., Avanzini M.A., Marconi M., Groff A., Cometa A., Cioni M., Porretti L., Barberi W., Frassoni F. and Locatelli F. (2008). Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol. Dial. Transplant. 23, 1196-1202
21. Conforti A., Scarsella M., Starc N., Giorda E., Biagini S., Proia A., Carsetti R., Locatelli F. and Bernardo M.E. (2014). Microvescicles derived from mesenchymal stromal cells are not as effective as their cellular counterpart in the ability to modulate immune responses in vitro. Stem Cells Dev. 23, 2591-2599
22. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., Risso M., Gualandi F., Mancardi G.L., Pistoia V. and Uccelli A. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107, 367-372
23. Covas D.T., Panepucci R.A., Fontes A.M., Silva W.A. Jr, Orellana M.D., Freitas M.C., Neder L., Santos A.R., Peres L.C., Jamur M.C. and Zago M.A. (2008). Multipotent mesenchymal stromal cells obtained from diverse human tissues share functional properties and geneexpression profile with CD146+ perivascular cells and fibroblasts. Exp. Hematol. 36, 642-654
24. Crop M.J., Baan C.C., Korevaar S.S., Ijzermans J.N., Weimar W. and Hoogduijn M.J. (2010). Human adipose tissue-derived mesenchymal stem cells induce explosive T-cell proliferation. Stem Cells Dev. 19, 1843-1853
25. Di Ianni M., Del Papa B., De Ioanni M., Moretti L., Bonifacio E., Cecchini D., Sportoletti P., Falzetti F. and Tabilio A. (2008). Mesenchymal cells recruit and regulate T regulatory cells. Exp. Hematol. 36, 309-318
26. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S. and Gianni A.M. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843
27. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., Noël D. and Jorgensen C. (2003). Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102, 3837-3844
28. Djouad F., Charbonnier L.M., Bouffi C., Louis-Plence P., Bony C., Apparailly F., Cantos C., Jorgensen C. and Noël D. (2007). Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 25, 2025-2032
29. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D.J. and Horwitz E. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317
30. English K., Barry F.P. and Mahon B.P. (2008). Murine mesenchymal stem cells suppress dendritic cell migration, maturation and antigen presentation. Immunol. Lett. 115, 50-58
31. English K., Ryan J.M., Tobin L., Murphy M.J., Barry F.P. and Mahon B.P. (2009). Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin. Exp. Immunol. 156, 149-160
32. Favaro E., Carpanetto A., Lamorte S., Fusco A., Caorsi C., Deregibus M.C., Bruno S., Amoroso A., Giovarelli M., Porta M., Perin P.C., Tetta C., Camussi G. and Zanone M.M. (2014). Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes. Diabetologia 57, 1664-1673
33. Fibbe W.E. and Noort W.A. (2003). Mesenchymal stem cells and hematopoietic stem cells transplantation. Ann. NY Acad. Sci. 996, 235-244
34. François M., Romieu-Mourez R., Stock-Martineau S., Boivin M.N., Bramson J.L. andd Galipeau J. (2009). Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigenpresenting cell properties. Blood 114, 2632-2638
35. Friedenstein A.J., Chailakhjan R.K. and Lalykina K.S. (1970). The development of fibroblast colonies in monolayer cultures of guineapig bone marrow and spleen cells. Cell Tissue Kinet. 3, 393-403
36. Friedenstein A.J., Gorskaja J.F. and Kulagina N.N. (1976). Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp. Hematol. 4, 267-274
37. Friedenstein A.J., Petrakova K.V., Kurolesova A.I. and Frolova G.P. (1968). Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6, 230-247
38. Gang E.J., Bosnakovski D., Figueiredo C.A., Visser J.W. and Perlingeiro R.C. (2007). SSEA-4 identifies mesenchymal stem cells from bone marrow. Blood 109, 1743-1751
39. Gieseke F., Böhringer J., Bussolari R., Dominici M., Handgretinger R. and Müller I. (2010). Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 116, 3770-3779
40. Gieseke F., Schütt B., Viebahn S., Koscielniak E., Friedrich W., Handgretinger R. and Müller I. (2007). Human multipotent mesenchymal stromal cells inhibit proliferation of PBMCs independently of IFNgammaR1 signaling and IDO expression. Blood 110, 2197-2200
41. Glennie S., Soeiro I., Dyson P.J., Lam E.W. and Dazzi F. (2005). Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105, 2821-2827
42. González M.A., Gonzalez-Rey E., Rico L., Büscher D. and Delgado M. (2009). Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum. 60, 1006-1019
43. Greco S.J., Liu K. and Rameshwar P. (2007). Functional similarities among genes regulated by OCT4 in human mesenchymal and embryonic stem cells. Stem Cells 25, 3143–3154
44. Groh M.E., Maitra B., Szekely E. and Koç O.N. (2005). Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol. 33, 928-934
45. Haniffa M.A., Wang X.N., Holtick U., Rae M., Isaacs J.D., Dickinson A.M., Hilkens C.M. and Collin M.P. (2007). Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells. J. Immunol. 79, 1595-1604
46. In't Anker P.S., Noort W.A., Scherjon S.A., Kleijburg-van der Keur C., Kruisselbrink A.B., van Bezooijen R.L., Beekhuizen W., Willemze R., Kanhai H.H. and Fibbe W.E. (2003a). Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 88, 845-852
47. In't Anker P.S., Scherjon S.A., Kleijburg-van der Keur C., Noort W.A., Claas F.H., Willemze R., Fibbe W.E. and Kanhai H.H. (2003b). Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 102, 1548-1549
48. In't Anker P.S., Scherjon SA., Kleijburg-van der Keur C., de Groot- Swings G.M., Claas F.H., Fibbe W.E. and Kanhai H.H. (2004). Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 22, 1338-1345
49. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D. and Mao N. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105, 4120-4126
50. Jones S., Horwood N., Cope A. and Dazzi F. (2007). The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J. Immunol. 179, 2824-2831
51. Kim J. and Hematti P. (2009). Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp. Hematol. 37, 1445-1453
52. Klyushnenkova E., Mosca J.D., Zernetkina V., Majumdar M.K., Beggs K.J., Simonetti D.W., Deans R.J. and McIntosh K.R. (2005). T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J. Biomed. Sci. 12, 47-57
53. Krampera M., Cosmi L., Angeli R., Pasini A., Liotta F., Andreini A., Santarlasci V., Mazzinghi B., Pizzolo G., Vinante F., Romagnani P., Maggi E., Romagnani S. and Annunziato F. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24, 386-398
54. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E. and Dazzi F. (2003). Bone marrow mesenchymal stem cells inhibit the response of naïve and memory antigen-specific T cells to their cognate peptide. Blood 101, 3722-3729
55. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E. and Ringdén O. (2003a). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31, 890-896
56. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E. and Ringdén O. (2003b). Mesenchymalstem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 57, 11-20
57. Lee R.H., Pulin A.A., Seo M.J., Kota D.J., Ylostalo J., Larson B.L., Semprun-Prieto L., Delafontaine P. and Prockop D.J. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6 Cell Stem Cell 5, 54-63
58. Liu Y., Wang L., Kikuiri T., Akiyama K., Chen C., Xu X., Yang R, Chen W., Wang S. and Shi S. (2011). Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN- γ and TNF-α. Nat. Med. 7, 1594-1601
59. Liu O., Xu J., Ding G., Liu D., Fan Z., Zhang C., Chen W., Ding Y., Tang Z. and Wang S. (2013). Periodontal ligament stem cells regulate B lymphocyte function via programmed cell death protein 1 Stem Cells 31, 1371-1382
60. Liu Y., Hu J. and Wang S. (2014). Mesenchymal stem cell-mediated treatment of oral diseases. Histol. Histopathol. 29, 1007-1015
61. Maccario R., Podestà M., Moretta A., Cometa A., Comoli P., Montagna D., Daudt L., Ibatici A., Piaggio G., Pozzi S., Frassoni F. and Locatelli F. (2005). Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90, 516-525
62. Maggini J., Mirkin G., Bognanni I., Holmberg J., Piazzón I.M., Nepomnaschy I., Costa H., Cañones C., Raiden S., Vermeulen M. and Geffner J.R. (2010). Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS. One 5, e9252
63. Maitra B., Szekely E., Gjini K., Laughlin M.J., Dennis J., Haynesworth S.E. and Koç O.N. (2004). Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 33, 597-604
64. Maqbool M., Vidyadaran S., George E. and Ramasamy R. (2011). Human mesenchymal stem cells protect neutrophils from serumdeprived cell death. Cell Biol. Int. 35, 1247-1251
65. Martinez C., Hofmann T.J., Marino R., Dominici M. and Horwitz E.M. (2007). Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs. Blood 109, 4245-4248
66. Martinet L., Fleury-Cappellesso S., Gadelorge M., Dietrich G., Bourin P., Fournié J.J. and Poupot R. (2009). A regulatory cross-talk between Vgamma9Vdelta2 T lymphocytes and mesenchymal stem cells. Eur. J. Immunol. 39, 752-762
67. McIntosh K., Zvonic S., Garrett S., Mitchell J.B., Floyd Z.E., Hammill L., Kloster A., Di Halvorsen Y., Ting J.P., Storms R.W., Goh B., Kilroy G., Wu X. and Gimble J.M. (2006). The immunogenicity of human adipose-derived cells: temporal changes in vitro. Stem Cells 24, 1246-1253
68. Meisel R., Zibert A., Laryea M., Göbel U., Däubener W. and Dilloo D. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103, 4619-4621
69. Mokarizadeh A., Delirezh N., Morshedi A., Mosayebi G., Farshid A.A. and Mardani K. (2012). Microvesicles derived from mesenchymal stem cells: potent organelles for induction of tolerogenic signaling. Immunol. Lett. 147, 47-54
70. Mougiakakos D., Jitschin R., Johansson C.C., Okita R., Kiessling R. and Le Blanc K. (2011). The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 117, 4826-4835
71. Nauta A.J., Kruisselbrink A.B., Lurvink E., Willemze R. and Fibbe W.E. (2006). Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J. Immunol. 177, 2080-2087
72. Nasef A., Mathieu N., Chapel A., Frick J., François S., Mazurier C., Boutarfa A., Bouchet S., Gorin N.C., Thierry D. and Fouillard L. (2007). Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 84, 231-237
73. Nasef A., Mazurier C., Bouchet S., François S., Chapel A., Thierry D., Gorin N.C. and Fouillard L. (2008). Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol. 253, 16-22
74. Németh K., Leelahavanichkul A., Yuen P.S., Mayer B., Parmelee A., Doi K., Robey P.G., Leelahavanichkul K., Koller B.H., Brown J.M., Hu X., Jelinek I., Star R.A. and Mezey E. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15, 42-49
75. Petrini I., Pacini S., Petrini M., Fazzi R., Trombi L. and Galimberti S. (2009). Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells. Eur. J. Clin. Invest. 39, 813-818
76. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S. and Marshak DR. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147
77. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S. and Rameshwar P. (2003). Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigen and recall antigens. J. Immunol. 171, 3426-3434
78. Prevosto C., Zancolli M., Canevali P., Zocchi M.R. and Poggi A. (2007). Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 92, 881-888
79. Prockop D.J. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276, 71-74
80. Rafei M., Campeau P.M., Aguilar-Mahecha A., Buchanan M., Williams P., Birman E., Yuan S., Young Y.K., Boivin M.N., Forner K., Basik M. and Galipeau J. (2009). Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 182, 5994-6002
81. Raffaghello L., Bianchi G., Bertolotto M., Montecucco F., Busca A., Dallegri F., Ottonello L. and Pistoia V. (2008). Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26, 151-162
82. Rasmusson I., Ringdén O., Sundberg B. and Le Blanc K. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76, 1208-1213
83. Rasmusson I., Le Blanc K., Sundberg B. and Ringdén O. (2007). Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand. J. Immunol. 65, 336-343
84. Ren G., Zhang L., Zhao X., Xu G., Zhang Y., Roberts A.I., Zhao R.C. and Shi Y. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141-150
85. Ren G., Su J., Zhang L., Zhao X., Ling W., L'huillie A., Zhang J., Lu Y., Roberts A.I., Ji W., Zhang H., Rabson A.B. and Shi Y. (2012). Species variation in the mechanisms of mesenchymal stem cellmediated immunosuppression. Stem Cells 27, 1954-1962
86. Romieu-Mourez R., François M., Boivin M.N., Stagg J. and Galipeau J. (2007). Regulation of MHC class II expression and antigen processing in murine and human mesenchymal stromal cells by IFNgamma, TGF-beta, and cell density. J. Immunol. 179, 1549-1558
87. Sánchez-Abarca L.I., Alvarez-Laderas I., Díez Campelo M., Caballero- Velázquez T., Herrero C., Muntión S., Calderón C., García-Guerrero E., Sánchez-Guijo F., Del Cañizo C., San Miguel J. and Pérez- Simón J.A. (2013). Uptake and delivery of antigens by mesenchymal stromal cells. Cytotherapy 15, 673-678
88. Sanchez-Ramos J., Song S., Cardozo-Pelaez F., Hazzi C., Stedeford T., Willing A., Freeman T.B., Saporta S., Janssen W., Patel N., Cooper D.R. and Sanberg PR. (2000). Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp. Neurol. 164, 247-256
89. Sato K., Ozaki K., Oh I., Meguro A., Hatanaka K., Nagai T., Muroi K. and Ozawa K. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109, 228-234
90. Schwartz R.E., Reyes M., Koodie L., Jiang Y., Blackstad M., Lund T., Lenvik T., Johnson S., Hu W.S. and Verfaillie C.M. (2002). Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J. Clin. Invest. 109, 1291-1302
91. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., Borg C., Saas P., Tiberghien P., Rouas-Freiss N, Carosella E.D. and Deschaseaux F. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26, 212-222
92. Shi S. and Gronthos S. (2003). Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J. Bone Miner. Res. 18, 696-704
93. Sotiropoulou P.A., Perez S.A., Gritzapis A.D., Baxevanis CN. and Papamichail M. (2006). Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24, 74-85
94. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C. and Moretta L. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107, 1484-1490
95. Spaggiari G.M., Capobianco A., Abdelrazik H., Becchetti F., Mingari M.C. and Moretta L. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2 Blood 111, 1327-1333
96. Spaggiari G.M., Abdelrazik H., Becchetti F. and Moretta L. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2 Blood 113, 6576-6583
97. Stagg J., Pommey S., Eliopoulos N. and Galipeau J. (2006). Interferongamma- stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 107, 2570-2577
98. Su J., Chen X., Huang Y., Li W., Li J., Cao K., Cao G., Zhang L., Li F., Roberts A.I., Kang H., Yu P., Ren G., Ji W., Wang Y. and Shi Y. (2014). Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ. 21, 388-396
99. Sun L., Akiyama K., Zhang H., Yamaza T., Hou Y., Zhao S., Xu T., Le A. and Shi S. (2009). Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27, 1421-1432
100. Tabera S., Pérez-Simón J.A., Díez-Campelo M., Sánchez-Abarca L.I., Blanco B., López A., Benito A., Ocio E., Sánchez-Guijo F.M., Cañizo C. and San Miguel J.F. (2008). The effect of mesenchymal stem cells on the viability, proliferation and differentiation of Blymphocytes. Haematologica 93, 1301-1309
101. Tang K.C., Trzaska K.A., Smirnov S.V., Kotenko S.V., Schwander S.K., Ellner J.J. and Rameshwar P. (2008). Down-regulation of MHC II in mesenchymal stem cells at high IFN-gamma can be partly explained by cytoplasmic retention of CIITA. J. Immunol. 180, 1826-1833
102. Traggiai E., Volpi S., Schena F., Gattorno M., Ferlito F., Moretta L. and Martini A. (2008). Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 26, 562-569
103. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C. and Guinan E.C. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75, 389-397
104. Wang L., Zhao Y. and Shi S. (2012). Interplay between mesenchymal stem cells and lymphocytes: implications for immunotherapy and tissue regeneration. J. Dent. Res. 91, 1003-1010
105. Yamaza T., Miura Y., Bi Y., Liu Y., Akiyama K., Sonoyama W., Patel V., Gutkind S. Young M., Gronthos S., Le A., Wang C.Y., Chen W. and Shi S. (2008). Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One 3, e2615
106. Yamaza T., Ren G., Akiyama K., Chen C., Shi Y. and Shi S. (2011). Mouse mandible contains distinctive mesenchymal stem cells. J. Dent. Res. 90, 317-324
107. Yang S.H., Park M.J., Yoon I.H., Kim S.Y., Hong S.H., Shin J.Y., Nam H.Y., Kim Y.H., Kim B. and Park C.G. (2009). Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10 Exp. Mol. Med. 41, 315-324
108. Zhang W., Ge W., Li C., You S., Liao L., Han Q., Deng W. and Zhao R.C. (2004). Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 13, 263-271
109. Zhang B., Liu R., Shi D., Liu X., Chen Y., Dou X., Zhu X., Lu C., Liang W., Liao L., Zenke M. and Zhao R.C. (2005). Mesenchymal stem cells induce mature dendritic cells into a novel Jagged-2-dependent regulatory dendritic cell population. Blood 113, 46-57
110. Zhang Q.Z., Su W.R., Shi S.H., Wilder-Smith P., Xiang A.P., Wong A., Nguyen A.L., Kwon C.W. and Le A.D. (2010). Human gingivaderived mesenchymal stem cells elicit polarization of m2 macrophages and enhance cutaneous wound healing. Stem Cells 28, 1856-1868
111. Zhao S., Wehner R., Bornhäuser M., Wassmuth R., Bachmann M. and Schmitz M. (2010). Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immunemediated disorders. Stem Cells Dev. 19, 607-614
112. Zuk P.A., Zhu M., Mizuno H., Huang J., Futrell J.W., Katz A.J., Benhaim P., Lorenz H.P. and Hedrick M.H. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 7, 211-228.